Disease Diagnosis TRIZ Cases

Biomarker detection methods quantify specific protein levels in blood samples to identify latent tuberculosis infection status.

Extraction of polypeptide markers from blood samples enables continuous disease burden monitoring without invasive bone marrow biopsies.

A flow cytometry method detects pathogenic B and T cells using specific protein marker combinations.

SRM/MRM mass spectrometry quantifies mesothelin protein levels in formalin-fixed tissues to resolve selectivity challenges in cancer therapy monitoring.

Measuring specific polypeptide and metabolite concentrations in cerebrospinal fluid samples enables early identification of rapid converters from clinically isolated syndrome.

A lateral flow immunochromatography device detects anti-Toxoplasma antibodies in whole blood samples using capillary action.

A multiplexed detection device uses aptamers and antibodies to identify multiple pathogens simultaneously.

A sample test method measures free fatty acid concentrations in subject samples to evaluate gynecological cancer presence.

Measuring dimeric IL-18 resolves inconsistent monomeric detection, improving diagnostic reliability.

Detecting anti-BC RNA autoantibodies via enzyme immunoassay identifies neuropsychiatric lupus risk without complex monitoring systems.

A cross-reactive nanoarray sensor system analyzes exhaled breath volatile organic compounds to differentiate multiple diseases through pattern recognition.

Analyzing ITIH3 protein concentration in plasma overcomes invasive endoscopy limitations and wide dynamic range noise to detect gastric cancer.

Quantifying stem cell memory T cell ratios in blood samples diagnoses cardiovascular disease severity without invasive tissue biopsies.

PG65 protein probe generates conformation-sensitive fluorescence signals to detect alpha synuclein oligomers.

Liquid-liquid phase separation extracts low-abundance biomarkers from biological fluids, resolving contamination issues in Alzheimer's diagnostics.

Using a cell-permeable denaturant to unfold endogenous targets reveals ligand binding through aggregation differences, avoiding recombinant protein artifacts.

Replacing complex ultrasound equipment, the immunoassay measures placental protein concentrations to estimate gestational age in low-resource settings.

Detecting proteolytically cleaved PTPμ fragments resolves the trade-off between surgical resection extent and tumor margin specificity in glioma treatment.

Quantifying urinary L-FABP levels predicts COVID-19 deterioration risk without exposing healthcare workers to viral droplets.

Peptides detect autoantibodies to Noggin and Sclerostin in patient samples.

Midregional proadrenomedullin detection resolves plasma instability bottlenecks to enable reliable invasive fungal infection diagnosis.

A protein extraction method using a specific lysis buffer enables sensitive chemical typing of amyloid deposits through electrophoretic separation.

In situ protein production on NAPPA arrays detects multiple autoantibodies, resolving late beta cell destruction diagnosis.

Soluble receptor-binding domains quantify granulocyte membrane receptors, enabling precise diagnosis of inflammatory states without complex mechanical assays.

Segmenting specific CD45RA+CD197-CD27-CD28- phenotypes resolves the contradiction between measurement precision and method complexity.

A hepatic cell system assesses bile acid homeostasis to identify toxicity profiles in candidate compounds.

Adapted Ma-104 cell line detects infectious African swine fever virus via red blood cell rosetting, replacing scarce primary swine macrophages.

Segmented antibody array detects specific amyloid biomarkers to resolve the contradiction between high measurement precision and low assay complexity.

Applying disease-specific procalcitonin thresholds to patient data resolves the trade-off between prognostic accuracy and false positive rates.

Blood-based biomarker combination differentiates ischemic from hemorrhagic stroke, resolving diagnostic accuracy versus imaging availability constraints.

Anti-NMU antibodies regulate insulin secretion by blocking the neuromedin U receptor, addressing limited prediction tools for diabetes treatment.

Iron chelators bind iron ions to stabilize liquid prothrombin time reagents, eliminating the need for freeze-drying and reconstitution steps.

A bioimpedance measurement system determines lean tissue mass to calculate glomerular filtration rate.

A method isolating free cholesterol and phospholipids to calculate lipoprotein particle quantities using geometric relationships.

A urine assay system detects sCD163 and MCP-1 biomarkers to identify active crescentic glomerulonephritis without invasive procedures.

Freezing and thawing blood samples releases intracellular prions for detection by heparin-enhanced RT-QuIC assays, achieving high sensitivity.

A serum cytokine panel predicts therapeutic response in rheumatoid arthritis patients before biological preparation administration.

A monoclonal antibody kit detects asialo-α1-acid glycoprotein concentrations in blood samples to track hepatocellular injury.

Single-molecule fluorescence detection identifies cardiac troponin within minutes, resolving the delay in acute coronary syndrome diagnosis.

Measuring pancreatic stone protein levels in serum samples to assess disease severity.

Adjusting implantable device parameters using predictive biomarker concentrations to optimize arrhythmia detection stringency.

A biomarker panel detects inflammatory markers to determine cardiovascular event risk, replacing insufficient diagnostic tests with prognostic stratification.

Segmenting PEG and protein components resolves assay complexity while enabling precise discrimination of anti-PEG antibodies across multiple isotypes.

Combining C3a-desArg, sTNFR1, and NGAL measurements resolves weak individual prognostic value of conventional tools by increasing prediction accuracy.

A flow cytometry-based assay quantifies platelet activation using labeled detection elements to determine heparin-induced thrombocytopenia status.

Mass spectrometry-based immunoassay quantifies progerin in plasma to resolve low detection sensitivity limits in clinical trials.

Multi-tissue proteomic profiling analyzes brain, CSF, and plasma samples to identify molecular signatures associated with Alzheimer's disease.

Nucleophosmin measurement differentiates atrial fibrillation from heart failure, preventing embolic events.